Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
This page reflects information as of May 2026
Gastrointestinal side effects of GLP-1s can be mitigated with appropriate dose escalation when initiating therapy
(2023) 277:e14452
Centers for Medicare and Medicaid Services (CMS) has announced that semaglutide, Novo Nordisks obesity drug sold under the brand name Wegovy, will be covered by Medicare if prescribed for its heart health benefits
US$ 29.14
US$ 29.25
US$ 22.37
US$ 26.80
US$ 22.30
